Selma Blair discussed her heartbreaking MS relapse during a candid chat on Tuesday's Drew Barrymore Show. The actress, 52, ...

There’s no news yet on its US list price. Along with other S1P drugs, it will also have to compete with Merck KGaA’s Mavenclad (cladribine), which has a difference mechanism of action but was ...

Gilenya was first approved in 2010 and has been a big brand for Novartis, although it is facing strong competition from newer drugs such as Roche's Ocrevus (ocrelizumab), Merck KGaA's Mavenclad ...

Mavenclad is taken by mouth in two yearly treatment courses. Each yearly treatment course consists of two cycles (lasting four or five days) that are about a month apart. Gilenya, Tascenso ODT ...

which is the active ingredient of the approved oral treatment Mavenclad, in relapsing multiple sclerosis (MS), showed comparable pharmacological properties to its name-brand counterpart.